Wandercraft wins FDA clearance for self-balancing exoskeleton

Wandercraft secured FDA clearance for Eve, a personal self-balancing exoskeleton aimed at adults with spinal cord injuries to support hands-free upright mobility. The company plans a US commercial launch with distribution partnerships and anticipates Medicare reimbursement eligibility within 90 days.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.